long intergenic non-protein coding RNA 533Genealiases: []
Q-omics provides the consensus-scored LINC00533 profile across patient tissues and cancer cell-line models. LINC00533 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC00533 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, LINC00533 RNA expression shows 12,229 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, THCA, and TGCT as cancer lineages where LINC00533 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00533 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00533 survival associations across molecular data types. LINC00533 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00533 RNA expression–survival associations across cancer types. High LINC00533 expression shows unfavorable associations in LUAD, COAD, UCEC and DLBC, but favorable associations in LAML and OV. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC00533 RNA expression.
This table summarizes LINC00533 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00533. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00533 shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRP, KIRC, KICH and LIHC. The THCA box plot shows higher LINC00533 RNA expression in normal versus tumor tissue (log2 FC = −0.628, t-test p < 0.001).
This table shows molecular features associated with LINC00533 in patient tissues and cancer cell lines. In patient samples, LINC00533 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
